Bolden Therapeutics, Inc.

About Bolden Therapeutics, Inc.

Bolden Therapeutics is a biotechnology company focused on developing first-in-class therapeutics to increase neurogenesis (the formation of new brain cells) for improving outcomes in neurological diseases. Their mission is to address cognitive dysfunction and memory impairment in conditions such as Alzheimer's disease by targeting novel signaling pathways.

Products & Services

Neurogenesis-Promoting Therapies:First-in-class therapeutics designed to increase neurogenesis for the treatment of neurological diseases, with potential applications in Alzheimer's disease, stroke recovery, treatment-resistant depression, Huntington's disease, Parkinson's disease, brain injury, and cognitive impairment following chemotherapy or COVID-19 exposure.

Antisense Oligonucleotides:Therapeutic modality using exon-skipping antisense oligonucleotides to promote neurogenesis, currently in preclinical development.

Specialties

Neurogenesis Neurological Disease Treatment Antisense Oligonucleotides Central Nervous System (CNS) Therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Pre-Seed Convertible Note T: - FT: Pre-Seed Convertible Note	A: 1500000 MR: - FA: 1.5M FAN: 1500000	D: 2024-01-17 FD: 2024-01-17	4 investors

Pre-Seed Convertible Note Latest

2024-01-17

$1.5M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Anne Valat

Director of Research

A

Ashley E. Webb

Scientific Founder, SAB Member

C

Charles Polsky

Executive Chairman

J

Joel Richter

SAB Member

J

Johnny Page

Co-Founder & CEO

J

Justin R. Fallon

Scientific Founder, SAB Chair

View 8 more team members with Pro

Unlock Full Team Directory

Recent News